AEON Biopharma (AEON) vs CalciMedica (CALC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AEON Biopharma (AEON) has outperformed CalciMedica (CALC) over the past year, losing 85.2% versus a loss of 92.3%. AEON Biopharma is the larger company by market cap ($10.3 million vs $8.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | CALC |
|---|---|---|
| Share price | $0.123 | $1.26 |
| Market cap | $10.35M | $8.69M |
| 1-day change | -7.59% | +7.69% |
| YTD return | -88.82% | -96.18% |
| 1-year return | -85.18% | -92.34% |
| EPS (TTM) | $-3.89 | $-4.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-39.22M | $-29.56M |
| 52-week high | $1.45 | $36.00 |
| 52-week low | $0.106 | $1.00 |
| Distance from 52-week high | -91.52% | -96.50% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1379.67% | +3868.25% |
| Average volume | 7.44M | 80.15K |
| Shares outstanding | 84.12M | 6.90M |
| Employees | 8 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
AEON vs CALC FAQ
Which is bigger, AEON Biopharma or CalciMedica?
AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $8.69M for CalciMedica (CALC).
Which stock has performed better over the past year, AEON or CALC?
AEON returned -85.18% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and CalciMedica in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.